Cover Image
市場調查報告書

禾本科花粉症:開發中產品分析

Grass Pollen Allergy - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 200453
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
Back to Top
禾本科花粉症:開發中產品分析 Grass Pollen Allergy - Pipeline Review, H1 2018
出版日期: 2018年02月27日 內容資訊: 英文 66 Pages
簡介

禾本科花粉過敏指的是一接觸禾本科植物的花粉馬上產生的過敏反應。主要的症狀·前兆有皮膚的反應(蕁麻疹·皮膚發紅·腫等),口·喉嚨附近發癢·刺痛,喉嚨僵硬、呼吸急促,喘鳴,鼻涕等。主要的易罹病素質有年齡和家族病史,其他的過敏體質等。

本報告提供全球各國治療禾本科植物花粉症所用的開發中產品之開發情形分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

禾本科花粉症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

禾本科花粉症:企業開發中的治療藥

禾本科花粉症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品

禾本科花粉症:企業開發中的產品

禾本科花粉症的治療藥的開發企業

  • ALK-Abello A/S
  • Allergy Therapeutics Plc
  • Biomay AG
  • Circassia Pharmaceuticals Plc
  • HAL Allergy BV
  • Roxall Medizin GmbH
  • 鹽野義製藥

禾本科花粉症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

禾本科花粉症:暫停中的計劃

禾本科花粉症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10192IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Grass Pollen Allergy - Pipeline Review, H1 2018, provides an overview of the Grass Pollen Allergy (Immunology) pipeline landscape.

Grass pollen allergy is a reaction which occurs soon after exposure to pollen from grasses. Signs and symptoms include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, tightening of the throat, shortness of breath or wheezing and runny nose. Predisposing factors include age, family history and other allergies.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Grass Pollen Allergy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Grass Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Grass Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 3, 2 and 2 respectively.

Grass Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Grass Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Grass Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Grass Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Grass Pollen Allergy (Immunology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Grass Pollen Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Grass Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Grass Pollen Allergy - Overview
    • Grass Pollen Allergy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Grass Pollen Allergy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Grass Pollen Allergy - Companies Involved in Therapeutics Development
    • ALK-Abello AS
    • Allergy Therapeutics Plc
    • ASIT Biotech SA
    • Biomay AG
    • HAL Allergy BV
    • Regeneron Pharmaceuticals Inc
  • Grass Pollen Allergy - Drug Profiles
    • Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BM-32 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dupilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gp-ASIT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Pollinex Quattro Grass - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine 1 for Grass Pollen Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Grass Pollen Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Grass Pollen Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Grass Pollen Allergy - Dormant Projects
  • Grass Pollen Allergy - Discontinued Products
  • Grass Pollen Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Jan 11, 2018: ASIT Biotech is Publishing a New Article on the Clinical Result of gp-ASIT+ in the Prestigious Science Journal ALLERGY
      • Dec 14, 2017: ASIT biotech reviews the efficacy results of gp-ASIT+ observed during the phase III trial completed in 2016
      • Dec 06, 2017: ASIT biotech significantly moves forward in the preparation of the clinical development plan of gp-ASIT+ in the US
      • Jul 03, 2017: ASIT biotech Presented the Immunogenicity Data of the gp-ASIT+ Phase III Clinical Study for the Treatment of Grass Pollen Rhinitis at EAACI 2017
      • Feb 27, 2017: ASIT biotech Will Publish the Results of the Phase 3 Clinical Trial with Its gp-ASIT+ Product Candidate for Treating Grass Pollen Rhinitis on 28 February, 2017
      • Jan 26, 2017: Biomay AG Reports Positive Results From A Second Phase IIb Trial With The Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32
      • Dec 05, 2016: ASIT+ technology's benefits in treating grass pollen rhinitis presented during a scientific session at Medical Research Council & Asthma UK Centre in London
      • Nov 14, 2016: ASIT biotech takes important steps in US clinical development of gp-ASIT+, its lead drug candidate for grass pollen rhinitis
      • Oct 05, 2016: ASIT biotech announces the last patient last visit in the Phase III clinical study with its first product candidate gp-ASIT+
      • Sep 08, 2016: Grass pollen allergy vaccine also effective against hepatitis B
      • Jun 27, 2016: Allergy Therapeutics announces findings from mEEC dose range finding study G204
      • Jun 13, 2016: New Data From GAP Landmark Trial Confirm GRAZAX Prevents Asthma Symptoms in Children
      • Mar 04, 2016: Inflamax Research Announces the Successful Completion of Enrollment for the First Multi-center, Mobile Environmental Exposure Chamber (mEEC) Study
      • Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL
      • Jan 28, 2016: Biomay initiates new phase II clinical trial with grass pollen allergy vaccine BM32
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Grass Pollen Allergy, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Grass Pollen Allergy - Pipeline by ALK-Abello AS, H1 2018
  • Grass Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H1 2018
  • Grass Pollen Allergy - Pipeline by ASIT Biotech SA, H1 2018
  • Grass Pollen Allergy - Pipeline by Biomay AG, H1 2018
  • Grass Pollen Allergy - Pipeline by HAL Allergy BV, H1 2018
  • Grass Pollen Allergy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
  • Grass Pollen Allergy - Dormant Projects, H1 2018
  • Grass Pollen Allergy - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Grass Pollen Allergy, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products by Stage and Targets, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top